Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Key Points The incidence of mutations within the MAPK pathway, the CRBN pathway, and TP53 is significantly increased in drug-refractory MM. Mutations in CRBN might contribute to IMiD resistance in drug-refractory MM.